Akili Expands Prescription Digital Therapeutics Portfolio with TALi Partnership
The creators behind EndeavorRx, the first FDA-approved game-based therapy for ADHD, signed a licensing agreement with another digital health company that is developing treatments to improve attention in children.
August 18, 2021
Akili Interactive, the developer behind the first FDA-approved game-based prescription treatment for ADHD, announced this week that it is partnering with TALi Digital, an Australian-based digital health company, to license its attention-improving game software in the U.S. provided FDA approval.
Under the deal, the two companies will work together to execute clinical trials of TALi’s video game-based technology — designed to screen for and improve early childhood attention impairments — in pediatric ADHD and pursue FDA regulatory clearance. Upon securing FDA approval, Akili will lead the treatment’s U.S. commercialization and roll-out.
The agreement complements Akili’s own flagship product, EndeavorRx, a game-based digital therapeutic to improve attention function in children with ADHD that received FDA approval last year.
TALi’s technology, marketed under TALi DETECT® and TALi TRAIN® (screening and attention training video games, respectively) has been shown to improve attention in neurodiverse and neurotypical children, especially in areas like numeracy skills, selective attention, and classroom behavior. The technology is currently available in Australia, India, Singapore, and Hong Kong.
